ES2366381T3 - Comprimido que contiene un ingrediente activo difícilmente soluble. - Google Patents

Comprimido que contiene un ingrediente activo difícilmente soluble. Download PDF

Info

Publication number: ES2366381T3
Authority: ES; Spain
Prior art keywords: tablet; active ingredient; preparation; present; hardly soluble
Prior art date: 2005-06-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES06767078T

Other languages

English (en)

Spanish (es)

Inventor

S. Marunaka

M. Fukuta

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharmaceutical Co Ltd

Original Assignee

Takeda Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-22

Filing date

2006-06-21

Publication date

2011-10-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37570471&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2366381(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-06-21 Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd

2011-10-19 Application granted granted Critical

2011-10-19 Publication of ES2366381T3 publication Critical patent/ES2366381T3/es

Status Active legal-status Critical Current

2026-06-21 Anticipated expiration legal-status Critical

Links

239000004480 active ingredient Substances 0.000 title description 30
239000003826 tablet Substances 0.000 claims abstract description 49
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 34
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 22
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 22
239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 21
235000019359 magnesium stearate Nutrition 0.000 claims abstract description 17
239000007864 aqueous solution Substances 0.000 claims abstract description 8
239000011230 binding agent Substances 0.000 claims abstract description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 3
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims abstract description 3
229940080818 propionamide Drugs 0.000 claims abstract description 3
238000002360 preparation method Methods 0.000 description 30
238000004090 dissolution Methods 0.000 description 21
239000008187 granular material Substances 0.000 description 12
239000000203 mixture Substances 0.000 description 9
125000001424 substituent group Chemical group 0.000 description 9
229940126062 Compound A Drugs 0.000 description 8
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 8
230000006399 behavior Effects 0.000 description 8
238000000034 method Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
229920002261 Corn starch Polymers 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
239000008120 corn starch Substances 0.000 description 6
229940099112 cornstarch Drugs 0.000 description 6
239000007888 film coating Substances 0.000 description 6
238000009501 film coating Methods 0.000 description 6
239000002245 particle Substances 0.000 description 6
239000000843 powder Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
230000000052 comparative effect Effects 0.000 description 5
238000009472 formulation Methods 0.000 description 5
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
235000021355 Stearic acid Nutrition 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
239000000654 additive Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
125000001183 hydrocarbyl group Chemical group 0.000 description 4
229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 4
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 4
239000008101 lactose Substances 0.000 description 4
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
239000008117 stearic acid Substances 0.000 description 4
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 4
YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 description 3
239000007941 film coated tablet Substances 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229960001150 ramelteon Drugs 0.000 description 2
238000005303 weighing Methods 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
229960000516 bezafibrate Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
208000020685 sleep-wake disease Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

ES06767078T 2005-06-22 2006-06-21 Comprimido que contiene un ingrediente activo difícilmente soluble. Active ES2366381T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2005-182415		2005-06-22
JP2005182415		2005-06-22

Publications (1)

Publication Number	Publication Date
ES2366381T3 true ES2366381T3 (es)	2011-10-19

Family

ID=37570471

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES06767078T Active ES2366381T3 (es)	2005-06-22	2006-06-21	Comprimido que contiene un ingrediente activo difícilmente soluble.

Country Status (18)

Country	Link
US (1)	US8821926B2 (ja)
EP (1)	EP1900368B1 (ja)
JP (1)	JP5220408B2 (ja)
KR (1)	KR20080027783A (ja)
CN (1)	CN101247805B (ja)
AU (1)	AU2006260201B2 (ja)
BR (1)	BRPI0611618A2 (ja)
CA (1)	CA2612090C (ja)
CR (1)	CR9632A (ja)
ES (1)	ES2366381T3 (ja)
HK (1)	HK1115315A1 (ja)
IL (1)	IL187916A (ja)
MX (1)	MX2007015783A (ja)
NO (1)	NO20080248L (ja)
NZ (1)	NZ564407A (ja)
RU (1)	RU2420278C2 (ja)
WO (2)	WO2006137443A1 (ja)
ZA (1)	ZA200711048B (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5361188B2 (ja) *	2006-08-10	2013-12-04	武田薬品工業株式会社	医薬組成物
WO2009084023A2 (en) *	2007-10-19	2009-07-09	Glenmark Generics Limited	Amorphous ramelteon and process for the preparation thereof
SG173001A1 (en) *	2009-01-21	2011-08-29	Hoffmann La Roche	Pharmaceutical compositions comprising a hcv polymerase inhibitor prodrug
TWI438200B (zh) *	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
US9532952B2 (en)	2011-01-28	2017-01-03	Physician's Seal, LLC	Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en)	2011-01-28	2012-08-02	Zx Pharma, Llc	Controlled-release melatonin composition and related methods
CN103989643B (zh) *	2013-07-26	2018-10-30	武汉先路医药科技有限公司	含有雷美替胺和共聚维酮的片剂
CN104546746A (zh) *	2013-10-28	2015-04-29	南京长澳医药科技有限公司	一种雷美替胺片剂及其制备工艺
JP2019514977A (ja)	2016-05-06	2019-06-06	フィジシャンズシール，エルエルシー	バレリアン組成物及び関連方法
JP7407364B2 (ja) *	2019-02-12	2024-01-04	日本ジェネリック株式会社	ラメルテオン含有固形製剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4786503A (en) *	1987-04-06	1988-11-22	Alza Corporation	Dosage form comprising parallel lamine
ES2175350T5 (es) *	1996-03-08	2008-12-16	Takeda Pharmaceutical Company Limited	Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
US6034239A (en)	1996-03-08	2000-03-07	Takeda Chemical Industries, Ltd.	Tricyclic compounds, their production and use
JP2884153B2 (ja) *	1996-03-08	1999-04-19	武田薬品工業株式会社	三環性化合物、その製造法および剤
JPH11322584A (ja) *	1998-05-07	1999-11-24	Sawai Pharmaceutical Co Ltd	ベザフィブラート徐放性製剤
KR100642024B1 (ko) *	1998-06-09	2006-11-06	다케다 야쿠힌 고교 가부시키가이샤	수면 장애를 치료 또는 예방하기 위한 약학적 조성물
CN1227001C (zh) *	1999-09-10	2005-11-16	兰贝克赛实验室有限公司	依托度酸的缓释制剂
DE60142305D1 (de)	2000-11-17	2010-07-15	Takeda Pharmaceutical	Pharmazeutische zubereitung enthaltend n-ä2-(1,6,7,8-tetrahydro-2h-indenoä5,4 büfuran-8-yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung
JP4848558B2 (ja) *	2001-05-08	2011-12-28	トーアエイヨー株式会社	塩酸メトホルミン含有速放性錠剤
JP4754211B2 (ja) *	2004-12-28	2011-08-24	ライオン株式会社	粒状医薬組成物及びその製造方法

2006
- 2006-06-21 ES ES06767078T patent/ES2366381T3/es active Active
- 2006-06-21 MX MX2007015783A patent/MX2007015783A/es active IP Right Grant
- 2006-06-21 US US11/922,769 patent/US8821926B2/en active Active
- 2006-06-21 RU RU2008102238/15A patent/RU2420278C2/ru not_active IP Right Cessation
- 2006-06-21 NZ NZ564407A patent/NZ564407A/en not_active IP Right Cessation
- 2006-06-21 WO PCT/JP2006/312419 patent/WO2006137443A1/ja active Application Filing
- 2006-06-21 BR BRPI0611618-3A patent/BRPI0611618A2/pt not_active IP Right Cessation
- 2006-06-21 CN CN2006800306256A patent/CN101247805B/zh active Active
- 2006-06-21 EP EP06767078A patent/EP1900368B1/en active Active
- 2006-06-21 KR KR1020077029802A patent/KR20080027783A/ko not_active Application Discontinuation
- 2006-06-21 ZA ZA200711048A patent/ZA200711048B/xx unknown
- 2006-06-21 AU AU2006260201A patent/AU2006260201B2/en not_active Ceased
- 2006-06-21 WO PCT/JP2006/312421 patent/WO2007004425A1/ja active Application Filing
- 2006-06-21 CA CA2612090A patent/CA2612090C/en active Active
- 2006-06-21 JP JP2007522318A patent/JP5220408B2/ja active Active
2007
- 2007-12-05 IL IL187916A patent/IL187916A/en not_active IP Right Cessation
- 2007-12-21 CR CR9632A patent/CR9632A/es unknown
2008
- 2008-01-14 NO NO20080248A patent/NO20080248L/no not_active Application Discontinuation
- 2008-09-08 HK HK08109975.2A patent/HK1115315A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
US20090036522A1 (en)	2009-02-05
WO2006137443A1 (ja)	2006-12-28
EP1900368B1 (en)	2011-05-11
RU2420278C2 (ru)	2011-06-10
EP1900368A1 (en)	2008-03-19
IL187916A (en)	2013-11-28
RU2008102238A (ru)	2009-07-27
NZ564407A (en)	2011-03-31
MX2007015783A (es)	2008-02-21
NO20080248L (no)	2008-01-14
ZA200711048B (en)	2009-05-27
KR20080027783A (ko)	2008-03-28
HK1115315A1 (en)	2008-11-28
AU2006260201B2 (en)	2011-10-20
IL187916A0 (en)	2008-03-20
CA2612090A1 (en)	2006-12-28
BRPI0611618A2 (pt)	2011-05-31
CN101247805B (zh)	2012-10-10
CN101247805A (zh)	2008-08-20
WO2007004425A1 (ja)	2007-01-11
AU2006260201A1 (en)	2006-12-28
CA2612090C (en)	2014-06-10
JPWO2006137443A1 (ja)	2009-01-22
CR9632A (es)	2008-02-04
US8821926B2 (en)	2014-09-02
EP1900368A4 (en)	2009-08-12
JP5220408B2 (ja)	2013-06-26

Publication	Publication Date	Title
ES2366381T3 (es)	2011-10-19	Comprimido que contiene un ingrediente activo difícilmente soluble.
US20190209479A1 (en)	2019-07-11	3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
PL200957B1 (pl)	2009-02-27	Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej
JP5517938B2 (ja)	2014-06-11	安定なトラネキサム酸とアスコルビン酸含有医薬組成物
KR20190015329A (ko)	2019-02-13	다파글리플로진 공결정의 약학 조성물
JP5579066B2 (ja)	2014-08-27	有効成分が境界を有してなる医薬固形製剤
JP2016104812A (ja)	2016-06-09	ロキソプロフェンナトリウム及びトラネキサム酸を含有する固形製剤
JP2021028326A (ja)	2021-02-25	レベチラセタムを含む錠剤
WO2008065339A1 (en)	2008-06-05	Pharmaceutical composition of memantine
EP3357492B1 (en)	2019-12-04	Multilayer tablet for administration of magnesium
CN109475557B (zh)	2022-01-07	含有甲氨蝶呤的薄膜包衣片
AU2016202063B2 (en)	2017-11-02	Novel pharmaceutical composition
JPH08325142A (ja)	1996-12-10	ヨウ化イソプロパミド含有製剤
JP4222802B2 (ja)	2009-02-12	ペルゴリド含有医薬組成物